Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leroy Darkes

Internal Medicine Garner, NC Medical Doctor

NPI 1326011396 CMS profile 14094

400 Health Park Dr Ste 100, Garner, NC 27529

Open in the dashboard

General payments

$3,184

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leroy Darkes of Garner, NC is reported in the CMS Open Payments database as having received $3,184 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $621 32
2024 General $1,136 65
2023 General $669 32
2022 General $585 18
2021 General $25 1
2020 General $46 3
2019 General $102 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leroy Darkes
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Leroy Darkes were reported at $621. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Leroy Darkes Internal Medicine median Middle half National median
2019 $102 $159 $48–$570 $163
2020 $46 $119 $33–$402 $114
2021 $25 $135 $37–$521 $132
2022 $585 $141 $42–$496 $149
2023 $669 $149 $45–$519 $160
2024 $1,136 $154 $47–$537 $164
2025 $621 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,059 48 payments
  2. Lilly USA, LLC $333 19 payments
  3. AstraZeneca Pharmaceuticals LP $308 10 payments
  4. Sumitomo Pharma America, Inc. $229 11 payments
  5. GlaxoSmithKline, LLC. $190 9 payments
  6. Amgen Inc. $177 15 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $132 8 payments
  8. Pfizer Inc. $118 6 payments
  9. Janssen Pharmaceuticals, Inc $112 8 payments
  10. Urovant Sciences Inc $103 1 payment
  11. Other $423 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,167 157 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $568 25 payments
  2. Ozempic $468 25 payments
  3. Wegovy $402 19 payments
  4. GEMTESA $352 13 payments
  5. MOUNJARO $230 13 payments
  6. FARXIGA $186 5 payments
  7. Otezla $162 14 payments
  8. Repatha $145 13 payments
  9. XARELTO $112 8 payments
  10. ZEPBOUND $110 6 payments
  11. Other $1,651 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 139 drugs

Part D claims

8,579

Median for Internal Medicine: 777

Drug cost

$630,200

Median for Internal Medicine: $73,373

Branded share of claims

18.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 111 $88,153
Rybelsus Semaglutide Brand 68 $73,426
Ozempic Semaglutide Brand 47 $67,456
Jardiance Empagliflozin Brand 30 $44,515
Januvia Sitagliptin Phosphate Brand 40 $36,643
Tradjenta Linagliptin Brand 25 $27,798
Xarelto Rivaroxaban Brand 22 $27,342
Mounjaro Tirzepatide Brand 23 $26,008
Myrbetriq Mirabegron Brand 42 $23,950
Farxiga Dapagliflozin Propanediol Brand 29 $22,303

The 10 drugs with the highest cost, of 139 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$40,041

Of which drugs: $6,523

Medicare patients

147

Average age 77

Services billed

599

77 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 35%
Arthritis 35%
Ischemic heart disease 22%
Cancer 19%
Chronic kidney disease 17%
Heart failure 14%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 41 41 $3,273
Sarscv2 vac 30mcg trs-suc im 91320 Office 11 11 $1,681

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $135
$135 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $110
$110 — —
RYBELSUS
  • Novo Nordisk Inc $102
$102 68 —
Ozempic
  • Novo Nordisk Inc $102
$102 47 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $102
$102 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record